![](\"https:\/\/mms.businesswire.com\/media\/20260601261177\/en\/794671\/5\/FMI_horizontal.jpg\")
<\/a><\/a>\nFoundation Medicine will bring its genomic testing capabilities and extensive expertise as a global leader in companion diagnostic (CDx) approvals, with 100 approved CDx indications, the most of any comprehensive genomic profiling company.1<\/sup> SWOG CTP\u2019s network of investigators and committees at over 1,300 sites in 47 states, including community hospitals, academic medical centers and National Cancer Institute-designated clinical cancer centers, can collaborate with Foundation Medicine on initiatives including multi-arm platform trials and registrational studies that may lead to future CDx applications. Trials can leverage Foundation Medicine\u2019s robust portfolio of high-quality tests and robust solutions designed for biopharmaceutical partners to support protocol design and uncover multi-omic insights in oncology.<\/p> \n\u201cSWOG CTP shares our commitment to advancing precision oncology by pursuing scientifically rigorous, cutting-edge biomarker-driven research,\u201d said Todd Druley, M.D, Ph.D., chief medical officer at Foundation Medicine. \u201cBy bringing Foundation Medicine\u2019s deep scientific, regulatory and genomic expertise to SWOG CTP and its broad investigator community, we can help accelerate new breakthroughs in biomarker-driven medicine, moving from discovery to impacting patient care in the clinic with speed and clarity.\u201d<\/p> \n\"SWOG CTP offers access to an extensive network of sites nationwide and the opportunity to move biomarker-driven science closer to the people who need it most,\u201d said Kathy S. Albain, M.D., SWOG vice chair for Clinical Trials Partnerships. \u201cThis formalized partnership marks an exciting step forward \u2013 one we believe will drive the translation of promising research into meaningful options for patients.\"<\/p> \nFoundation Medicine\u00ae<\/sup> is a registered trademark of Foundation Medicine, Inc.<\/i><\/p> \nAbout Foundation Medicine<\/b><\/p> \nFoundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases. We provide tests and solutions to transform care throughout a patient\u2019s experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring. We help accelerate the development of new personalized therapies by leveraging our vast knowledge of precision medicine, real world data and AI-powered tools, expanding the information our diagnostic solutions provide to enable improved outcomes for patients. Every day, we are inspired to think differently to transform the lives of people living with cancer and other diseases. For more information, visit us at www.FoundationMedicine.com<\/a> and follow us on LinkedIn<\/a>, X<\/a>, YouTube<\/a>, Facebook<\/a>, Instagram<\/a> and BlueSky<\/a>.<\/p> \nAbout SWOG Clinical Trials Partnerships<\/b><\/p> \nSWOG Clinical Trials Partnerships (SWOG CTP) is an independent, limited liability corporation formed in 2008 by The Hope Foundation for Cancer Research, the charitable arm of SWOG Cancer Research Network. SWOG CTP supports the mission of SWOG to significantly improve lives through cancer clinical trials and translational research. SWOG CTP distributes non-federal funding for components of SWOG studies and conducts independent trials through industry partnerships, including its Preferred Partnership Program. Learn more at swogctp.org.<\/p>\n
\n __________________________\u00a0<\/td>\n<\/tr>\n \n